Irritable bowel syndrome (IBS) is a chronic, relapsing disorder of gut–brain interaction characterized by abdominal pain and altered bowel habits in the absence of identifiable structural pathology. Although it is not dangerous in the sense of causing intestinal damage, IBS can substantially impair quality of life, contribute to work absenteeism, and co-occur with anxiety and depressive disorders. Clinically, IBS is defined by symptom-based criteria: recurrent abdominal pain associated with defecation and/or changes in stool frequency or form. Subtypes include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed stool patterns (IBS-M), and unclassified IBS.
Pathophysiology in IBS is multifactorial. Central to current models is dysregulation of the bidirectional gut–brain axis involving visceral hypersensitivity, altered motility, immune and epithelial dysfunction, and alterations in the gut microbiome. Visceral hypersensitivity arises from enhanced afferent signaling and impaired descending inhibitory pathways within the central nervous system. Patients may perceive normal colonic distension as painful or uncomfortable, partly due to sensitization of spinal and supraspinal circuits. Motility alterations include abnormal transit times, segmental contractions, and impaired coordination of gut movements, leading to constipation, urgency, bloating, or diarrhea depending on the dominant pattern.
Immune activation and low-grade mucosal inflammation can be present, particularly after infectious gastroenteritis, a scenario termed post-infectious IBS. In such cases, persistent changes in intestinal barrier function and immune signaling may amplify symptom generation. Intestinal epithelial dysfunction can increase permeability, facilitating luminal antigen exposure and cytokine-mediated changes in sensory pathways. Microbiome dysbiosis is supported by evidence of altered microbial composition and metabolite profiles; microbial fermentation products can influence gas production, stool consistency, and mucosal signaling.
Psychological factors are clinically relevant but not merely “all in the head.” Stress can modulate gut permeability, motility, and nociceptive processing. Neuroendocrine pathways, including corticotropin-releasing hormone signaling, affect intestinal inflammation and motility. Functional neuroimaging studies demonstrate altered brain processing of visceral stimuli in IBS, with altered connectivity between limbic, insular, and prefrontal regions. This framework explains why cognitive, emotional, and behavioral interventions can improve symptoms even when they do not directly target gut physiology.
Diagnosis relies on positive symptom criteria and exclusion of alarm features. Common red flags include gastrointestinal bleeding, unintentional weight loss, nocturnal symptoms that awaken the patient, persistent vomiting, family history of colorectal cancer, iron-deficiency anemia, and onset after age 50 without prior history. When alarm features exist or symptoms are atypical, laboratory testing (e.g., complete blood count, C-reactive protein, celiac serology) and selected investigations such as colonoscopy may be appropriate. For many patients meeting Rome criteria, routine endoscopy is not necessary if no alarm features are present.
Management is stepped and individualized. Education and reassurance are foundational, emphasizing the functional nature of IBS while validating symptom burden. Dietary strategies include adequate fiber, preferably soluble fiber for IBS-C, and a trial of low-fermentable carbohydrate approaches such as a low-FODMAP diet under dietitian guidance to reduce luminal gas and osmotic load. For IBS-D, bile acid diarrhea should be considered in selected cases; loperamide can reduce stool frequency, while antispasmodics may help pain. Pharmacologic options differ by subtype: osmotic laxatives such as polyethylene glycol may assist constipation; secretagogues and prokinetic agents may be considered when standard measures fail. For global symptom control, neuromodulators can be effective: tricyclic antidepressants (particularly at low doses) help pain and bowel pattern in IBS, while selective serotonin reuptake inhibitors may be useful in constipation- or anxiety-associated patterns.
Evidence-based psychological therapies—particularly cognitive behavioral therapy, gut-directed hypnotherapy, and stress-management interventions—can reduce symptom severity and improve coping. These approaches target maladaptive threat appraisal, attention to visceral sensations, and behavioral reinforcement cycles that perpetuate discomfort. Exercise and sleep optimization are also associated with symptom improvement, likely through effects on stress physiology and motility regulation.
Prognosis is generally favorable regarding mortality, but symptoms often follow a chronic course with fluctuations. Treatment aims are to improve pain, normalize bowel habits when feasible, reduce distress, and prevent escalation from functional symptoms into persistent disability. A comprehensive approach—combining dietary modulation, targeted medications by subtype, and psychological and lifestyle interventions—best addresses the gut–brain mechanisms driving IBS.
Source: [uniindianews/Source Link]
United News of India: Union Minister for Petroleum and Natural Gas Hardeep Singh Puri met Mohsen Paknejad, Minister of Petroleum of Iran, on the sidelines of BRICS Energy Ministers’ Meeting. @PetroleumMin | @MEAIndia | @India_in_Iran | @HardeepSPuri | #HardeepSinghPuri | #MohsenPaknejad |. #breaking
— @uniindianews May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
